Policy Options to Address Prescription Drug Costs and Affordability for Beneficiaries

Stacie B. Dusetzina, Ph.D., is an associate professor in the Department of Health Policy and an Ingram associate professor of cancer research at Vanderbilt. She is a health services researcher whose work focuses on measuring and evaluating population-level use and costs of medications in the United States. Dr. Dusetzina’s work has contributed to the evidence base for the role of drug costs on patient access to care and policy changes that might improve patient access to high-priced drugs. She has been recognized for her work at a national level, including being an invited participant for two working group meetings on “Patient Access to Affordable Cancer Drugs,” hosted by the President’s Cancer Panel, and being selected to co-author a National Academies of Sciences, Engineering and Medicine report on the same topic. Dr. Dusetzina’s research has also been broadly covered by NPR, Reuters, The Washington Post, STAT News, ABC News and The Wall Street Journal.

Contact: s.dusetzina@vanderbilt.edu

Lovisa Gustafsson, MBA, is vice president of the Controlling Health Care Costs program at the Commonwealth Fund where she focuses on commercial healthcare prices and drug pricing policy. Prior to joining the Fund, Ms. Gustafsson served as senior vice president for the Marwood Group, a health care advisory organization, where she managed various outsourced private equity due diligence and strategy consulting engagements. Before her role at the Marwood Group, she worked as a manager in corporate strategy and business development at McKesson, a senior consulting associate in quality and operations support for Kaiser Permanente, a senior policy analyst at the Commonwealth of Massachusetts Office of Medicaid, and a manager at Avalere Health LLC. Ms. Gustafsson earned an M.B.A. in health care management from the Wharton School at the University of Pennsylvania and a B.A. in sociology from Harvard University.

Contact: ilg@cmwf.org

Marianne Hamilton Lopez, Ph.D., MPA, is research director of the Value-Based Payment Reform portfolio at Duke-Margolis. In this role, she manages the Center’s activities aimed at identifying barriers and facilitating implementation of new value-based payment models for pharmaceuticals, including gene therapies, and medical devices. She oversees the Developing a Path to Value-Based Reimbursement for Medical Products Consortium and partners with Duke University faculty, scholars, and external health experts to advance this work. Prior to joining Duke-Margolis, Dr. Hamilton Lopez was a senior program officer with the National Academy of Medicine’s Leadership Consortium for a Value & Science-Driven Health System and provided strategic direction and oversight of the Consortium’s Science and Technology portfolio and Clinical Effectiveness Research Innovation and the Digital Learning Collaboratives. She was a Senior Manager at AcademyHealth; a Public Health Community Advisor for the United States Cochrane Center; and the Federal Women’s Program Manager and American Indian/Alaska Native Employment Program Manager for the National Institutes of Health.

Contact: marianne.hamilton.lopez@duke.edu

Kristi Martin, MPA, provides policy and strategic counsel expertise through her consulting firm, Highway 136 Consulting, to advance meaningful health policy. She draws on years of experience working in the public sector, with private sector clients, and in philanthropy. Most recently, she was vice president for health care at Arnold Ventures. In this role, she managed and advised on strategy for lowering prescription drug prices. Prior to joining Arnold Ventures, she was managing director of the health practice at Waxman Strategies, a consulting firm led by former Congressman Henry Waxman. Kristi served several years at the U.S. Department of Health and Human Services, Office of Personnel Management, and Government Accountability Office. As a senior advisor in the Obama administration’s Office of Health Reform, she had primary oversight responsibility for the coordinated and timely implementation of cross-cutting departmental public health and prevention initiatives, including addressing the rising cost of drugs and setting up the women’s preventive services initiative.

Contact: kristi@highway136.com